Nebracetam | CAS#97205-34-0

MedKoo Cat#: 341597 | Name: Nebracetam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nebracetam is a biochemical.

Chemical Structure

Nebracetam

CAS#97205-34-0

Theoretical Analysis

MedKoo Cat#: 341597

Name: Nebracetam

CAS#: 97205-34-0

Chemical Formula: C12H16N2O

Exact Mass: 204.1263

Molecular Weight: 204.27

Elemental Analysis: C, 70.56; H, 7.90; N, 13.71; O, 7.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Nebracetam; WEB-1881; WEB 1881 WEB1881,

IUPAC/Chemical Name

2-Pyrrolidinone, 4-(aminomethyl)-1-(phenylmethyl)-

InChi Key

LCAFGJGYCUMTGS-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2

SMILES Code

O=C1N(CC2=CC=CC=C2)CC(CN)C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 204.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ma J, Lin J, Zhao L, Harms K, Marsch M, Xie X, Meggers E. Synthesis of beta-Substituted gamma-Aminobutyric Acid Derivatives via Enantioselective Photoredox Catalysis. Angew Chem Int Ed Engl. 2018 Apr 30. doi: 10.1002/anie.201804040. [Epub ahead of print] PubMed PMID: 29714818. 2: Melendez MM, Xu X, Sexton TR, Shapiro MJ, Mohan EP. The importance of basic science and clinical research as a selection criterion for general surgery residency programs. J Surg Educ. 2008 Mar-Apr;65(2):151-4. doi: 10.1016/j.jsurg.2007.08.009. PubMed PMID: 18439541. 3: Gabryel B, Pudełko A, Trzeciak HI, Cieślik P. Effect of nebracetam on content of high-energy phosphates and morphometry of rat astrocytes in vitro. Comparison with piracetam. Acta Pol Pharm. 2000 Jul-Aug;57(4):289-98. PubMed PMID: 11126618. 4: Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, Oshikawa S. Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats. Br J Pharmacol. 1997 Jun;121(3):477-84. PubMed PMID: 9179389; PubMed Central PMCID: PMC1564714. 5: Takeo S, Hayashi H, Tadokoro M, Takagi K, Miyake K, Takagi N, Oshikawa S. Effects of nebracetam on synaptosomal monoamine uptake of striatal and hippocampal regions in rats. Biol Pharm Bull. 1997 Apr;20(4):360-3. PubMed PMID: 9145210. 6: Takeo S, Miyake K, Tanonaka K, Takagi N, Takagi K, Kishimoto K, Suzuki M, Katsuragi A, Goto M, Oshikawa S. Beneficial effect on nebracetam on energy metabolism after microsphere-induced embolism in rat brain. Arch Int Pharmacodyn Ther. 1996 May-Jun;331(3):232-45. PubMed PMID: 9124996. 7: Nakashima MN, Kataoka Y, Yamashita K, Kohzuma M, Ichikawa M, Niwa M, Kohno Y, Taniyama K. Histological evidence for neuroprotective action of nebracetam on ischemic neuronal injury in the hippocampus of stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1995 Jan;67(1):91-4. PubMed PMID: 7745852. 8: Kataoka Y, Kohno Y, Watanabe Y. Inhibitory action of nebracetam on various stimuli-evoked increases in intracellular Ca2+ concentrations in cultured rat cerebellar granule cells. Jpn J Pharmacol. 1995 Jan;67(1):87-90. PubMed PMID: 7745850. 9: Gillis JC, Benefield P, McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging. 1994 Aug;5(2):133-52. Review. PubMed PMID: 7981485. 10: Ohjimi H, Kushiku K, Yamada H, Kuwahara T, Kohno Y, Furukawa T. Increase of acetylcholine release by nebracetam in dog cardiac sympathetic ganglion. J Pharmacol Exp Ther. 1994 Jan;268(1):396-402. PubMed PMID: 7905531. 11: Urakami K, Shimomura T, Ohshima T, Okada A, Adachi Y, Takahashi K, Asakura M, Matsumura R. Clinical effect of WEB 1881 (nebracetam fumarate) on patients with dementia of the Alzheimer type and study of its clinical pharmacology. Clin Neuropharmacol. 1993 Aug;16(4):347-58. PubMed PMID: 8104098. 12: Yamamoto T, Ohno M, Yatsugi S, Fujikawa Y, Ueki S. Nootropic candidates inhibit head-twitches induced by mescaline in mice. Jpn J Pharmacol. 1992 Jul;59(3):419-21. PubMed PMID: 1434136. 13: Aoshima H, Shingai R, Ban T. Effect of nebracetam on nicotinic and muscarinic acetylcholine receptors expressed in Xenopus oocyte by injecting exogenous mRNA. Arzneimittelforschung. 1992 Jun;42(6):775-80. PubMed PMID: 1418030. 14: Kataoka Y, Niwa M, Koizumi S, Watanabe S, Kouzuma M, Taniyama K. Nebracetam (WEB 1881FU) prevents N-methyl-D-aspartate receptor-mediated neurotoxicity in rat striatal slices. Jpn J Pharmacol. 1992 Jun;59(2):247-50. PubMed PMID: 1279253. 15: Shibata S, Kagami-ishi Y, Ueki S, Watanabe S. Neuroprotective effect of WEB 1881 FU (nebracetam) on an ischemia-induced deficit of glucose uptake in rat hippocampal and cerebral cortical slices and CA1 field potential in hippocampal slices. Jpn J Pharmacol. 1992 Mar;58(3):243-50. PubMed PMID: 1355146. 16: Iwasaki K, Matsumoto Y, Fujiwara M. Effect of nebracetam on the disruption of spatial cognition in rats. Jpn J Pharmacol. 1992 Feb;58(2):117-26. PubMed PMID: 1507518. 17: Hashimoto M, Hashimoto T, Kuriyama K. Protective effect of WEB 1881 FU on AF64A (ethylcholine aziridinium ion)-induced impairment of hippocampal cholinergic neurons and learning acquisition. Eur J Pharmacol. 1991 Dec 10;209(1-2):9-14. PubMed PMID: 1814764. 18: Kushiku K, Ohjimi H, Yamada H, Furukawa T. Presynaptic facilitation by the new nootropic drug nebracetam, of ganglionic muscarinic transmission in the dog cardiac sympathetic ganglion. Arzneimittelforschung. 1991 Nov;41(11):1113-8. PubMed PMID: 1725696. 19: Kitamura Y, Kaneda T, Nomura Y. Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80. PubMed PMID: 2041225. 20: Ohno M, Yamamoto T, Kitajima I, Ueki S. WEB 1881 FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runway task. Jpn J Pharmacol. 1990 Sep;54(1):53-60. PubMed PMID: 2273648.